Meeting
2022 ASCO Annual Meeting
Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.
Authors
Amit M. Oza
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Amit M. Oza , Stephanie Lheureux , Ainhoa Madariaga , Mihaela C. Cristea , Gina Mantia-Smaldone , Alexander Olawaiye , Susan Ellard , Johanne I Weberpals , Andrea Elisabeth Wahner Hendrickson , Gini F. Fleming , Stephen Welch , Neesha C. Dhani , Vanessa Speers , Valerie Bowering , Lisa Wang , Wenjiang Zhang , Eric Xueyu Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5579)
DOI
10.1200/JCO.2022.40.16_suppl.5579
Abstract #
5579
Poster Bd #
455
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
First Author: Victor Manuel Villalobos
Poster
2018 ASCO Annual Meeting
A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.
First Author: Niven R. Narain
Poster
2012 ASCO Annual Meeting
Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).
First Author: Andrew X. Zhu
Poster
2011 ASCO Annual Meeting
First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
First Author: W. R. Schelman